pyrazolanthrone has been researched along with Familial Nonmedullary Thyroid Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cui, D; Xu, J; Zhao, Y | 1 |
| Bosari, S; Cirello, V; Colombo, C; Ferrero, S; Fugazzola, L; Grassi, ES; Persani, L; Ricca, D; Vaira, V; Vezzoli, V; Vicentini, L | 1 |
2 other study(ies) available for pyrazolanthrone and Familial Nonmedullary Thyroid Cancer
| Article | Year |
|---|---|
Activation of CXCL5-CXCR2 axis promotes proliferation and accelerates G1 to S phase transition of papillary thyroid carcinoma cells and activates JNK and p38 pathways.
Topics: Animals; Anthracenes; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL5; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mice, Nude; Phenylurea Compounds; Phosphorylation; Pyridines; Receptors, Interleukin-8B; Recombinant Proteins; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Anthracenes; Antineoplastic Agents; beta Catenin; Carcinoma, Papillary; Case-Control Studies; Cell Movement; Cell Proliferation; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Protein Kinases; rho-Associated Kinases; Signal Transduction; Spheroids, Cellular; Thyroid Cancer, Papillary; Thyroid Gland; Thyroid Neoplasms; Tumor Cells, Cultured | 2017 |